Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Spina bifida

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15651
R64607
Blotière (Indications other than epilepsy), 2019 Spina bifida 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.55 [0.10;24.87] C 0/980   616/1,875,733 616 980
ref
S15601
R64289
Tinker (Mixed indications), 2019 Spina bifida 1st trimester case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 1.30 [0.40;4.40] 3/24   1,238/12,750 1,241 24
ref
Total 2 studies 1.34 [0.44;4.02] 1,857 1,004
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Indications other than epilepsy), 2019Blotière, 2019 1 1.55[0.10; 24.87]61698016%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker (Mixed indications), 2019Tinker, 2019 2 1.30[0.40; 4.40]1,2412484%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 0% 1.34[0.44; 4.02]1,8571,0040.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.55[0.10; 24.87]616980 -NABlotière (Indications other than epilepsy), 2019 1 case control studiescase control studies 1.30[0.39; 4.31]1,24124 -NATinker (Mixed indications), 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.34[0.44; 4.02]1,8571,0040%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 Tags Adjustment   - No  - No 1.34[0.44; 4.02]1,8571,0040%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.55[0.10; 24.87]616980 -NABlotière (Indications other than epilepsy), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 1.30[0.39; 4.31]1,24124 -NATinker (Mixed indications), 2019 1 All studiesAll studies 1.34[0.44; 4.02]1,8571,0040%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.34[0.44; 4.02]1,8571,0040%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.510.01.0